Anika Therapeutics to Present at MassMEDIC MedTech Investors Conference.

Business Editors

MassMEDIC MedTech Investors Conference

WOBURN, Mass.--(BUSINESS WIRE)--Nov. 10, 2003

Anika Therapeutics, Inc. (Nasdaq:ANIK) today said that Chief Executive Officer Charles H. Sherwood, Ph.D. is scheduled to present at the MassMEDIC MedTech Investors Conference on Friday, November 14 at 10:00 a.m. EST at the Park Plaza Hotel in Boston. Dr. Sherwood will present an overview of the company and discuss current products, product pipeline, growth drivers and recent financial performance. Some of the information to be presented by Dr. Sherwood may contain information that has not been previously disclosed.

The presentation will be open to all interested parties through a live conference call. Those interested in listening to the presentation should call 877-292-2287 five minutes prior to the beginning of the scheduled presentation.

About Anika Therapeutics, Inc.

Headquartered in Woburn, Mass., Anika Therapeutics, Inc. (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. In addition to ORTHOVISC(R), a treatment for osteoarthritis of the knee (not approved for sale in the U.S.), Anika markets HYVISC(R) in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures AMVISC(R) and AMVISC(R) Plus, HA viscoelastic products for ophthalmic surgery, for Bausch & Lomb. It also produces CoEase(TM), which is marketed by Advanced Medical Optics, Inc., STAARVISC(TM)-II distributed by STAAR Surgical Company and Shellgel(TM) for Cytosol Ophthalmics, Inc.

The statements made in this press release which are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, statements that may be identified by words such as "expectations," "remains," "focus," "expected," "prospective," "expanding," "building," "continue," "progress," "efforts," "hope," "believe," "objectives," opportunities," "will," "seek," and other expressions which are predictions of or indicate future events and trends and which do not constitute historical matters identify forward-looking statements. The statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. The Company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors including the results of its research and development efforts and timing of regulatory approvals. There can be no assurances that the Company's increased unit sales will materially increase product revenue or improve gross margins. Certain other factors that might cause the Company's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors and Certain Factors Affecting Future Operating Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in each of the Company's Annual Report on Form 10-K for the year ended December 31, 2002, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2003 and Current Reports on Form 8-K, as well as those described in the Company's other press releases and SEC filings.